Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study

Conclusions:
Slow-release formulations of LHRH agonists are useful therapies for physicians treating patients with PCa and there may be a preference for the 6-month formulation.

Source: Therapeutic Advances in Urology - November 18, 2014 Category: Urology & Nephrology Authors: Lebret, T., Davin, J.-L., Hennequin, C., Latorzeff, I., Mignard, J.-P., Moreau, J.-L., Rossi, D., Ruffion, A., Zerbib, M., Culine, S. Tags: Original Research Source Type: research